@inproceedings{inproceedings, title  = {{Updated Survival, Quality of life (QOL) and Safety-data of Radium223 Dichlorid (Ra223) in patients with castration resistant prostate cancer (CRPC) with bone metastasis from the Phase 3 double-blind randomised, multinational study (ALSYMPCA)}},

 url = {{}},

 year = {{2013}},

 month = {{10}},

 author = {{Steuber T and Heinzer H and Haese A and Stroelin P and Parker C and Coleman RE and Nilsson S and Vogelzang N and Loyd AJ and Staudacher K and van Gool R et al}},

 volume = {{36}},

 journal = {{ONKOLOGIE}},

 pages = {{18-18}},

 note = {{Accessed on 2025/10/10}}}